- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00689507
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
June 25, 2015 updated by: Applied Molecular Evolution
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
H9S-MC-JDCF was a multicenter non-randomized, single-arm, open-label, dose-escalation, dose confirmation, Phase 1 study of intravenous (IV) LY2127399 in combination with bortezomib in patients with refractory or relapsed MM.
Study Overview
Detailed Description
This is a study of a drug known as LY2127399, which will be given with a common treatment for multiple myeloma called bortezomib (Velcade).
The primary purpose of this study is to (1)Determine the safety of LY2127399 in combination with bortezomib and any side effects that might be associated with it; (2)Assess whether LY2127399 in combination with bortezomib may help patients with relapsed or refractory multiple myeloma; (3)How much LY2127399 should be given to patients along with bortezomib.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-3300
- University Of Alabama
-
-
California
-
Los Angeles, California, United States, 90024
- UCLA
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have relapsed or refractory multiple myeloma treated with at least 1 prior regimen. Prior therapy with bortezomib is allowed if there has been no relapse or progression within 3 months of the last dose of bortezomib, and bortezomib is considered by the treating physician to be a reasonable therapy for the patient.
Have measurable disease defined by one or more of the following:
- Monoclonal protein in the serum of ≥1 g/dL (10 g/L).
- Monoclonal light chain in the urine protein electrophoresis of ≥ 200 mg/24 hours.
- Involved Serum Free Light Chain (SFLC) level > 10 mg/dL (100 mg/L) provided SFLC ratio is abnormal.
- Measurable plasmacytoma.
- Are ≥ 18 years of age.
- Have given written informed consent prior to any study-specific procedures
Have adequate organ function including:
- Absolute neutrophil count (ANC) ≥ 1000/microliter
- Platelet (PLT) count ≥ 50,000/microliter
- Hemoglobin (Hgb) ≥ 8.0 g/dL
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (if total is elevated check direct and, if normal, patient is eligible)
- Aspartate transaminase (AST) ≤ 3 x ULN
- Creatinine ≤ 3.0 mg/dl.
- Have a performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale (refer to Attachment JDCF.5).
- Have discontinued all previous therapies for cancer, including chemotherapy and radiotherapy at least 2 weeks (6 weeks for mitomycin-C or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy.
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
- Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 4 months following the last dose of study drug.
- Females with child bearing potential must have had a negative urine or serum pregnancy test ≤ 3 days prior to the first dose of study drug.
- Have an estimated life expectancy of ≥ 16 weeks.
- Treatment with prior autologous transplant is permitted. If a transplant is used as consolidation following chemotherapy, without intervening disease progression, it will be considered one line of treatment with the preceding chemotherapy.
Exclusion Criteria:
- Have received treatment within 30 days of the initial dose of study drug with a drug that has not received regulatory approval for any indication.
- Have one or more serious preexisting medical conditions that, in the opinion of the investigator, would preclude participation in this study.
- Have uncontrolled infection.
- Females who are pregnant or lactating.
- Have known positive test results in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb).
- Have peripheral neuropathy of > Grade 2, or of any grade with pain, as measured by CTCAE v3.0.
- Previously treated with LY2127399, or have had significant allergy to humanized monoclonal antibodies that, in the opinion of the investigator, poses an increased risk to the patient.
- Prior allogeneic hematopoietic stem cell transplant.
- Prior therapy with experimental agents targeting BAFF.
- Have QTc interval > 450 msec on baseline 12-lead ECG.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation Phase(Part A):
1,10, 30, 100 or 300 mg of LY2127399 IV on day 1 of specific 21 day cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each 21 day cycle
|
monoclonal antibody
|
Experimental: Dose Confirmation Phase (Part B1):
Dose determined by PK/PD modeling, LY2127399 IV on day 2 of Cycle 1 and on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each cycle
|
monoclonal antibody
|
Experimental: Dose Confirmation Phase (Part B2):
Dose determined by PK/PD modeling, LY2127399 IV on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of specific cycles
|
monoclonal antibody
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic (PK)/Pharmacodynamic (PD)modeling of LY2127399 to determine a Phase 2 dose
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and toxicity profile for LY2127399 in combination with bortezomib
Time Frame: 2 years
|
2 years
|
Response rate, duration of response, and time to progression of LY2127399 in combination with bortezomib
Time Frame: 2 years
|
2 years
|
Response rate, duration of response, and time to progression of LY2127399 as a single-agent
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Susan Carpenter, PhD, Applied Molecular Evolution
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (Actual)
January 1, 2013
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
May 29, 2008
First Submitted That Met QC Criteria
May 29, 2008
First Posted (Estimate)
June 3, 2008
Study Record Updates
Last Update Posted (Estimate)
June 29, 2015
Last Update Submitted That Met QC Criteria
June 25, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- H9S-MC-JDCF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on LY2127399
-
Eli Lilly and CompanyCompletedRheumatoid ArthritisUnited States, Mexico, Hungary, Chile, Germany, Puerto Rico, Australia, Belgium, Romania, Poland, India, Brazil, Austria, Canada
-
Eli Lilly and CompanyTerminatedRheumatoid ArthritisArgentina, Germany, India, Korea, Republic of, United States, Hungary, Taiwan, Bulgaria, France, Russian Federation, Spain, Ukraine, Colombia, Mexico, Poland, Japan, Croatia, Greece, New Zealand, Romania, South Africa, Australia, Br... and more
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyTerminated
-
Eli Lilly and CompanyTerminatedRheumatoid ArthritisUnited States, Germany, Taiwan, France, Japan, Mexico, Poland, Russian Federation, Spain, Colombia, Argentina, Greece, New Zealand, South Africa, Australia, Korea, Republic of, Brazil, Italy, Malaysia
-
Eli Lilly and CompanyCompletedRelapsing-Remitting Multiple SclerosisHungary, United States, France, Ukraine, Poland, Germany, Israel, Russian Federation, Czechia, Serbia, Romania, Slovakia, Bulgaria
-
Eli Lilly and CompanyCompletedRheumatoid ArthritisArgentina, India, United States, Hungary, Bulgaria, Mexico, Ukraine, Colombia, Taiwan, Poland, Japan, Korea, Republic of, New Zealand, Romania, South Africa, Australia, Croatia, Lithuania, Malaysia, Russian Federation, Slovakia, Sri...
-
Eli Lilly and CompanyCompletedSystemic Lupus Erythematosus | Autoimmune Disease | Connective Tissue DiseaseIndia, United States, Hungary, Romania, Spain, France, Taiwan, Russian Federation, United Kingdom, Australia, Latvia, Mexico, South Africa, Canada, Israel, Brazil, Serbia, Ecuador, Malaysia, New Zealand, Tunisia
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyTerminatedSystemic Lupus Erythematosus | Autoimmune Disease | Connective Tissue DiseaseUnited States